Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Melanoma/Skin Cancer
•
Dermatology
What patient characteristics or clinical scenarios guide the decision in performing slow Mohs procedures?
Related Questions
What criteria are used to select patients who have locally advanced BCC patients for treatment with sonidegib?
Have you considered intralesional cempilumab for locally advanced NMSC/KCs prior to surgery?
How would you treat a basal cell carcinoma on the temporal skin and zygomatic area s/p excision with PNI and significant flaps for closure?
How would you manage a patient who developed stage III melanoma while receiving cemiplimab (cycle 10) for locally advanced cutaneous squamous cell carcinoma?
Would you consider proceeding with a sentinel lymph node biopsy after wide excision revealed 1.2 mm residual non-ulcerated T2a melanoma on the upper back?
In what clinical scenarios do you consider pre- or post-treatment with Imiquimod for cutaneous melanoma?
What biologics would you use in a patient with rheumatoid arthritis who developed multiple basal cell carcinomas requiring Mohs surgery while on a TNF-inhibitor and did not respond to rituximab?
Is there a general consensus on margins to use when treating SCCIS or BCC with ED&C?
Have you used itraconazole as a primary or adjunct therapy for individuals with numerous BCCs?
How should the use of the DecisionDx-Melanoma test be integrated into clinical practice to potentially avoid sentinel lymph node biopsy?
